Manipulating the Metabolism to Improve the Efficacy of CAR T-Cell Immunotherapy

Research output: Contribution to journalReview articlepeer-review


The adoptive transfer of the chimeric antigen receptor (CAR) expressing T-cells has produced unprecedented successful results in the treatment of B-cell malignancies. However, the use of this technology in other malignancies remains less effective. In the setting of solid neoplasms, CAR T-cell metabolic fitness needs to be optimal to reach the tumor and execute their cytolytic function in an environment often hostile. It is now well established that both tumor and T cell metabolisms play critical roles in controlling the immune response by conditioning the tumor microenvironment and the fate and activity of the T cells. In this review, after a brief description of the tumoral and T cell metabolic reprogramming, we summarize the latest advances and new strategies that have been developed to improve the metabolic fitness and efficacy of CAR T-cell products.

Original languageEnglish
Issue number1
Publication statusPublished - Dec 24 2020


  • cancer
  • Chimeric Antigen Receptor T cells
  • combined therapy
  • immunotherapy
  • metabolic reprogramming

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Manipulating the Metabolism to Improve the Efficacy of CAR T-Cell Immunotherapy'. Together they form a unique fingerprint.

Cite this